Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
EMJ GOLD
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
BMS announces $2.3bn Houston manufacturing investment
Bristol Myers Squibb will invest $2.3bn in a new Houston manufacturing facility and create 500 jobs.
Read more
BMS announces $2.3bn Houston manufacturing investment
Bristol Myers Squibb will invest $2.3bn in a new Houston manufacturing facility and create 500 jobs.
Eli Lilly’s weight loss pill wins double UK approval
Eli Lilly has secured UK regulatory approval for weight management and type 2 diabetes.
FDA approves Takeda's first-in-class narcolepsy drug
Takeda’s Orzeyful is designed to treat the disease itself, not just its symptoms.
mRNA flu vaccine wins FDA nod despite rocky road
The first mRNA flu vaccine has been approved by the FDA for adults aged 50 and older.
Gilead reports strong Q2 driven by HIV portfolio
Total revenue increased 10% year-on-year to $7.8bn.
12 years after Pfizer, AstraZeneca reaches for BMS
The deal would rank among the largest in pharmaceutical history.
World-first trial delivers personalised lung cancer vaccine
The first patient has received a personalised lung cancer vaccine in a world-first clinical trial for advanced non-small cell lung cancer.
Sanofi lifts 2026 outlook as dupilumab tops €5bn
Sanofi raises its full-year 2026 guidance following strong Q2 results, with dupilumab surpassing €5bn in quarterly sales for the first time.
Loading posts...
1
2
3
…
58
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View